TOP STORIES
haematology
Clotting disorders

Caplacizumab approved for acquired Thrombotic Thrombocytopenic Purpura

A novel nanobody therapy caplacizumab (Cablivi) has been approved by the TGA as a treatment for acquired Thrombotic Thrombocytopenic Purpura (aTTP). The humanised nanobody therapy is approved in Australia to treat adults experiencing an episode of aTTP in conjunction with plasma exchange and immunosuppression. According to manufacturer Sanofi, caplacizumab binds to the protein von Willebrand ...

Already a member?

Login to keep reading.


OR
© 2020 the limbic